Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the <i>Fmr1</i>-KO Mouse Model of Fragile X Syndrome

Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the <i>Fmr1</i>-KO Mouse Model of Fragile X Syndrome

Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remain...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Marika Premoli, William Fyke, Luigi Bellocchio, Valerie Lemaire, Marie Wolley-Roberts, Bruno Bontempi, Susanna Pietropaolo
Materialtyp: Artikel
Språk:English
Publicerad: MDPI AG 2023-07-01
Serie:Cells
Ämnen:
phytocannabinoids
<i>Fmr1</i>
mouse behavior
neurodevelopmental disorders
interleukins
neurotrophins
Länkar:https://www.mdpi.com/2073-4409/12/15/1927

Internet

https://www.mdpi.com/2073-4409/12/15/1927

Liknande verk